340 W. 10th Street
Indianapolis, IN 46202-5175
Dr. Chalasani completed medical school in India before he moved to the U.S. to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), interim Chair of the Department of Medicine (2020-2021) and currently serves as the Vice President for Academic Affairs at Indiana University Health. He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999, and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 105 and 60,000 citations (as of Feb 2023). He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP). He has mentored more than 100 trainees and junior faculty members with 19 of his former mentees in faculty positions at major academic centers and 12 are current or former recipients of federal funding. During his tenure as the Division Chief, Dr. Chalasani took the Division of Gastroenterology and Hepatology to new heights, acclaiming national and international reputation, and leading excellence in health care, cutting edge research and teaching.
- Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. PNPLA3 rs 738409 and risk of fibrosis in NAFLD: exploring mediation pathways through intermediate histological features. Hepatology 2022. March 29. Online Ahead of Print
- Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Belt P, Liang T, Liu W, Chalasani N. Impact of the association between PNPLA3 genetic variation and dietary intake on the risk for significant fibrosis in patients with NAFLD. Am J Gastroenterol 2020. 116:994-1006.
- Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The protection conferred by HSD17B13 rs72613567 polymorphism on liver histology severity may be limited to selected subgroups of patients with NAFLD. Clinical and Translational Gastroenterol 2021; 159: 929-943 PMID 34506335
- Vilar-Gomez E, Sookoian S, Pirola CJ, Liang T, Gawrieh S, Cummings O, Liu W, Chalasani NP. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. 2020 Sep;159(3):929-943.
- Li YJ, Phillips E, Dellinger A, Nicoletti P, Schutte R, Li D, Ostrov DA, Fontana RJ, Watkins PB, Stolz A, Daly AK, Aithal GP, Barnhart H, Chalasani N; Drug-induced Liver Injury Network (DILIN); HLA-B*14:01 and HLA-B*35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury 2021; 73: 268-281
- Chalasani N, Bonkovsky HL, Stine JG, Gu J, Barnhart H, Jacobsen E, Bjornsson E, Fontana RJ, Kleiner DE, Hoofnagle JH. Clinical characteristics of liver injury due to antiepileptic drugs in patients from the DILIN Prospective Study. Journal of Hepatology 2021. Dec 22. Online ahead od print. PMID 34953957
- Vuppalanchi R, Caldwell SH, Pursopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuathala R, Sheikh F, Bainbridge JD, Parmar DV, Chalasani NP. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol 2021. Sept 3. (Epub ahead of print)
- Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Loomba R, Chalasani N, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385: 1559-1569.
- Gawrieh S, Noureddin M, Loo N, Mohseni R, Awatsy V, Cusi K, Kowdley KV, Lai, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a dual PPARα/? agonist, for treatment of nonalcoholic fatty liver disease: a randomized, controlled, double-blind trial. Hepatology 2021; 74: 1809-1824
Titles & Appointments
- David W. Crabb Professor of Gastroenterology and Hepatology
- Professor of Medicine
- Adjunct Professor of Anatomy, Cell Biology & Physiology
- Vice President for Academic Affairs, Indiana University Health